Login to Your Account

Financings Roundup

Friday, October 19, 2012

• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said it terminated its proposed convertible preferred stock offering due to current market conditions. The company, which is developing cancer drug PV-10, had filed a preliminary prospectus supplement in September. Shares of Provectus (NASDAQ:PVCT) gained 12 cents, or 23 percent, to close Thursday at 65 cents.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription